City Therapeutics has dosed the first participant in its Phase 1 clinical trial of CITY-RBP4, an RNA interference therapy targeting Stargardt disease, a genetic condition causing vision loss. CITY-RBP4 aims to reduce retinol-binding protein 4 (RBP4) to slow retinal damage by limiting vitamin A delivery to the eye. The trial will assess safety and drug effects, with initial data expected by mid-2027. This marks City Therapeutics' second program in clinical testing, advancing their pipeline of RNAi treatments for serious diseases.
City Therapeutics' recent dosing of the first participant in its Phase 1 trial for CITY-RBP4 is noted here alongside Pluang's health sector market snapshot. Of 150 priced health-sector US stocks tradable on Pluang, 85 rose and 56 fell as of Nov 10, 2026 18:42 WIB. Notable movers include FLNA at USD 0.53 with a 7.80% increase and a typical hold time of 39 days, CGC at USD 0.65 up 4.37%, and ABCL at USD 12.96 rising 3.68%, with Pluang order activity heavily weighted to selling for all three.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
